JAK Janus Kinase

Aus coViki
(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
K
 
(4 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt)
Zeile 1: Zeile 1:
 +
{{up|PHA Biologicals}}
 +
{{qt|Baricitinib}}
 +
{{qt|Fedratinib}}
 +
{{qt|Jaktinib}}
 +
{{qt|Methotrexate}}
 +
{{qt|Ruxolitinib}}
 +
{{qt|Tofacitinib}}
  
 
{{ttp|p=32584421|t=2020. Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer.|pdf=|usr=011}}
 
{{ttp|p=32584421|t=2020. Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer.|pdf=|usr=011}}
Zeile 10: Zeile 17:
 
{{tp|p=32537890|t=2020. Observation and consideration on using of JAKi in clinical trials in times of COVID-19.|pdf=|usr=010}}
 
{{tp|p=32537890|t=2020. Observation and consideration on using of JAKi in clinical trials in times of COVID-19.|pdf=|usr=010}}
 
{{tp|p=32580895|t=2020. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.|pdf=|usr=011}}
 
{{tp|p=32580895|t=2020. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.|pdf=|usr=011}}
 
+
{{tp|p=32592721|t=2020. Natural cardenolides suppress coronaviral replication by downregulating JAK1 via a Na(+)/K(+)-ATPase independent proteolysise.|pdf=|usr=018}}
 
+
{{tp|p=32726783|t=2020. JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients.|pdf=|usr=017}}
'''Tofacitinib'''
+
{{tp|p=32789663|t=2020. Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19.|pdf=|usr=018}}
 
+
{{tp|p=32847819|t=2020. Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 4: The role of JAK inhibition.|pdf=|usr=019}}
{{tp|p=32342098|t=ä. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib |pdf=|usr=}}
+
{{tp|p=32918336|t=2020. Janus Family kinase (JAK) inhibitors in HLH and severe COVID-19.|pdf=|usr=019}}
 
+
{{tp|p=33187978|t=2020. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.|pdf=|usr=020}}
'''Baricitinib'''
+
{{ttp|p=33245005|t=2020. JAK-STAT pathway inhibition and their implications in COVID-19 therapy.|pdf=|usr=021}}
{{tp|p=32259575|t=ä. BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF  COVID 19 |pdf=|usr=}}
+
{{tp|p=32779813|t=2020. Rugosic acid A, derived from Rosa rugosa Thunb., is novel inhibitory agent for NF-kappaB and IL-6/STAT3 axis in acute lung injury model.|pdf=|usr=018}}
{{tp|p=32333918|t=ä. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact |pdf=|usr=}}
+
{{tp|p=32032529|t=2020. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease |pdf=|usr=}}
+
{{tp|p=32473600|t=2020. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.|pdf=|usr=007}}
+
{{tp|p=32251638|t=2020. Baricitinib for COVID-19: a suitable treatment?|pdf=|usr=}}
+
{{tp|p=32251639|t=2020. Baricitinib for COVID-19: a suitable treatment? - Authors  reply |pdf=|usr=}}
+
{{tp|p=32437019|t=2020. Baricitinib: A chance to treat COVID-19?|pdf=|usr=007}}
+
{{tp|p=32542785|t=2020. Baricitinib: A review of pharmacology, safety and emerging clinical experience in COVID-19.|pdf=|usr=010}}
+
{{tp|p=32597466|t=2020. Use of Baricitinib in Patients with Moderate and Severe COVID-19.|pdf=|usr=011}}
+
{{tp|p=32592703|t=2020. Retrospective, multicenter study on the impact of baricitinib in COVID-19 moderate pneumonia.|pdf=|usr=011}}
+
{{tp|p=32583654|t=2020. Baricitinib en el tratamiento de infeccion por SARS-CoV-2.|pdf=|usr=011}}
+
 
+
'''Fedratinib'''
+
{{ttp|p=32205092|t=ä. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib |pdf=|usr=}}
+
 
+
'''Ruxolitinib'''
+
{{tp|p=32450201|t=2020. Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports.|pdf=|usr=008}}
+
{{tp|p=32470486|t=2020. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.|pdf=|usr=008}}
+
{{tp|p=32405693|t=2020. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?|pdf=|usr=008}}
+
{{tp|p=32518419|t=2020. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.|pdf=|usr=009}}
+
{{tp|p=32528040|t=2020. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.|pdf=|usr=009}}
+
{{tp|p=32585295|t=2020. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.|pdf=|usr=010}}
+
{{tp|p=32555296|t=2020. Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).|pdf=|usr=010}}
+
{{tp|p=32593183|t=2020. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.|pdf=|usr=011}}
+
{{tp|p=32581810|t=2020. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study.|pdf=|usr=011}}
+
 
+
'''Jaktinib'''
+
{{tp|p=32536632|t=2020. Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19.|pdf=|usr=011}}
+
 
+
 
+
'''Methotrexate mtx'''
+
{{tp|p=32454489|t=2020. JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.|pdf=|usr=007}}
+

Aktuelle Version vom 11. April 2021, 19:59 Uhr

PHA Biologicals
Baricitinib
Fedratinib
Jaktinib
Methotrexate
Ruxolitinib
Tofacitinib
32584421 2020. Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer.


32278797 ä. The use of Janus kinase inhibitors in the time of SARS-CoV-2
32339701 ä. Potential role of Janus kinase inhibitors in COVID-19
32344070 ä. Calm before the storm: understanding the role of JAK inhibitors in COVID-19

32535597 2020. Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19.


32385052 2020. ...The potential role of JAK inhibitors in the management of COVID-19.
32392562 2020. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
32584762 2020. [Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].
32537890 2020. Observation and consideration on using of JAKi in clinical trials in times of COVID-19.
32580895 2020. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.
32592721 2020. Natural cardenolides suppress coronaviral replication by downregulating JAK1 via a Na(+)/K(+)-ATPase independent proteolysise.
32726783 2020. JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients.
32789663 2020. Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19.
32847819 2020. Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 4: The role of JAK inhibition.
32918336 2020. Janus Family kinase (JAK) inhibitors in HLH and severe COVID-19.
33187978 2020. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.

33245005 2020. JAK-STAT pathway inhibition and their implications in COVID-19 therapy.


32779813 2020. Rugosic acid A, derived from Rosa rugosa Thunb., is novel inhibitory agent for NF-kappaB and IL-6/STAT3 axis in acute lung injury model.

Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis